The Dutch contract research firm is folding biophysics and X ray crystallography (the method that resolves a compound's 3D binding pose on its target) into its DNA barcoded compound screening service, betting that owning the follow up will turn a low yield platform into a…
For years, drug discovery teams have run DNA-encoded library screens to cast a wide net for candidate compounds. The screens work by attaching short DNA barcodes to each molecule in a vast library, mixing the library against a target protein, and using next-generation sequencing to read out which barcodes, and therefore which compounds, stuck. The problem, by general account in the field, is that DEL campaigns routinely generate more hits than a discovery team can realistically follow up, and most of those candidates do not survive the off-DNA resynthesis and structural characterization that real drug programs require.
A new service from ZoBio, the Dutch drug-discovery contract research organization, is built around that follow-up gap. According to the announcement carried by Genetic Engineering & Biotechnology News, the Leiden-based company is folding quantitative biophysics, off-DNA validation, and X-ray crystallography into a single service contract aimed at exploratory drug discovery programs. The pitch, attributed by GEN to ZoBio chief scientific officer Gregg Siegal, is that "off-DNA validation and structural characterization should not be optional add-ons" to a DEL hit list but the default deliverable.
That framing targets a class of targets that have long frustrated conventional high-throughput screening. Protein-protein interactions and binding pockets without clear features, the shallow, hydrophobic interfaces that define much of transcription-factor and scaffolding-protein biology, defeat most small-molecule discovery campaigns because they offer few anchoring interactions for a random library to exploit. DEL was supposed to brute-force that problem with library size, but raw affinity is not the same as druggability. A hit that does not survive resynthesis off the DNA tag, or that has no interpretable binding mode, is not a starting point. It is a dead end with a sequence read attached.
The open question is whether bundling the validation step into the screening contract actually changes the attrition math, or simply moves the bottleneck from one vendor to the client's medicinal chemistry team. ZoBio is making a bet that the answer is yes, and that drug companies will pay for the certainty of a structure-confirmed starting point rather than a list of candidates to triage themselves. That claim is, for now, a vendor argument. The announcement is a single-source launch notice, and no head-to-head comparison of bundled versus traditional DEL-plus-follow-up workflows has been published.
What to watch: whether competing providers respond with similar bundled offerings in the months ahead, and whether any group publishes a prospective study in which an integrated workflow produces a development candidate that a traditional DEL-plus-follow-up pipeline would have missed on the same target.